前收市價 | 0.1000 |
開市 | 0.2000 |
買盤 | 0.1000 |
賣出價 | 0.2500 |
拍板 | 7.50 |
到期日 | 2024-09-20 |
今日波幅 | 0.1700 - 0.2000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 812 |
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript May 2, 2024 Puma Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations were $-0.16. PBYI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name is Camilla, […]